Navigation Links
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Date:10/29/2009

discontinuation rates for disturbance in attention that were at least three times greater than what was observed in our studies. These results were consistent with the expected profile and previous experience of Qnexa in our studies," stated Leland Wilson, president and chief executive officer of VIVUS. "We believe this additional data further substantiates the safety profile of Qnexa. Taken in the context of the statistically significant weight loss and improvement on co-morbidities, Qnexa has a positive benefit/risk profile. Completion rates for patients on Qnexa were significantly better as compared to placebo in the phase 3 trials. We believe the overall efficacy and safety profile of Qnexa supports approvability."

The company anticipates filing the NDA for Qnexa by the end of 2009.

Previously reported highlights from the EQUIP and CONQUER studies were included in the presentation:

  • Average weight loss of 14.7% (37 lbs) was achieved by patients treated with Qnexa for 56 weeks in the EQUIP study;
  • Significant improvements in cardiovascular, metabolic and inflammatory risk factors among patients treated with Qnexa;
  • FDA efficacy benchmarks for weight loss agents were exceeded at all three doses of Qnexa tested in the clinical program; and
  • Completion rates up to 69% were significantly higher than placebo at all three doses of Qnexa, indicating favorable tolerability.
  • Across both 56-week studies, the most commonly reported side effects were dry mouth, tingling, constipation, altered taste and insomnia.
  • There were no serious adverse events reported for cognitive disorders.

EQUIP (OB-302) Study Overview

The EQUIP study included 1,267 morbidly obese patients (1,050 females and 217 males) across 93 centers in the United States. The average baseline BMI of the study population was 42.1 kg/m(2) and baseline weight was 256 pounds. Patients had
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Amgen (Nasdaq: AMGN ) announced today ... Medicines Agency (EMA) for a re-examination of the negative ... Products for Human Use (CHMP) for the use of Vectibix ... KRAS metastatic colorectal cancer (mCRC). Amgen ...
... SAN DIEGO, March 30, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ... City.   The live presentation takes place ... / 10:20 a.m. Pacific Time.  The presentation will be webcast ...
Cached Medicine Technology:Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 2Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 3Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 4Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 5Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 6Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 7Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 8Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe 9
(Date:7/10/2014)... (July 10, 2014) Men who experience hot flashes ... may find relief from their silent suffering if ... to findings from a Baylor University case study., After ... who had uncontrolled hot flashes following prostate cancer surgery ... but also an impressive improvement in sleep quality, according ...
(Date:7/9/2014)... 10, 2014 -- The World Health Organization recommends that ... moderate to vigorous physical activity (MVPA) each day. ... MVPA during school hours. Therefore, it stands to ... increase MVPA. In a new study scheduled for ... confirmed that time spent outdoors after school was positively ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... Researchers at the Perelman School of Medicine at ... Park Cancer Institute have received an $8 million grant ... effects of photodynamic light therapy (PDT) in patients with ... that most often manifests itself in the lining of ... to asbestos. The grant will fund a clinical trial ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
Breaking Medicine News(10 mins):Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2
... (OTC Bulletin Board: MACM) announced today that all ... converted their shares of preferred,stock into 12,571,850 shares ... shares of common stock previously issued with the ... 17,885,848 shares with an,exercise price of $.60 per ...
... Abbott has been named to,Hispanic Business magazine,s ... was recognized as one of the magazine,s "Diversity ... promotion, marketing,philanthropy and supplier diversity. "As an ... our,people to provide different ideas, perspectives and experience ...
... drink it daily lose less bone, study finds , , ... suggests that having a cuppa (tea, that is) may ... that drinking tea in moderation can actually benefit your ... in the nutrition program at the School of Exercise, ...
... For the first time,comprehensive information on long term ... it will be available from a single source: ... Today, LTC Financial,Partners (LTCFP), the nation,s most experienced ... CareScout, creator of the first,quality-of-care ratings on nursing ...
... Oct. 10 Adaptis, a leading provider of,Business ... has completed two company fundraising initiatives. One took ... the other in Yakima,Washington, where its regional operations ... way to involve Adaptis employees in goodwill,programs in ...
... may not have to get sick this flu,season. ... get your flu shot now.,But, not enough people ... deaths annually. Listen to this report from ... access video, audio, text, graphics and,photos for free ...
Cached Medicine News:Health News:MacroChem Announces Preferred Stock Conversions and $3.5 Million Private Placement 2Health News:MacroChem Announces Preferred Stock Conversions and $3.5 Million Private Placement 3Health News:Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine 2Health News:Tea Helps Toughen Older Women's Hips 2Health News:Tea Helps Toughen Older Women's Hips 3Health News:LTC Financial Partners (LTCFP) Engages CareScout to Bring Comprehensive Long Term Care Solutions to LTCFP Clients; A One-Stop Shop for All Care Information - An Industry First 2Health News:Adaptis Supports Local Yakima-Based YWCA and National Diabetes 2
...
... System is a complete anterior ... portable, it offers high-end performance ... console. It also provides all ... segment surgery. These include Irrigation, ...
... tool designed for ophthalmic surgeons. ... reliable, safe and easy to ... (one year for ultrasonic handpiece). ... console, phaco handpiece, foot pedal, ...
Oncoseed sterile convenience pack contains fifteen Oncoseed seeds (Model 6711) loaded into a Mick disposable cartridge and steam sterilized ready to use....
Medicine Products: